{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:58:13Z","timestamp":1781647093892,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gemcitabine plus albumin-bound paclitaxel is widely used as first-line therapy for unresectable pancreatic cancer, but it is frequently complicated by chemotherapy-induced peripheral neuropathy, which may lead to functional impairment and treatment modification. Factors associated with clinically relevant neuropathy, defined as grade 2 or higher, remain insufficiently clarified. This study aimed to identify factors associated with the development of grade\u2009\u2265\u20092 neuropathy during therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective observational study using medical records of patients with unresectable pancreatic cancer who received this combination therapy at Rakuwakai Otowa Hospital from April 2015 to March 2024. Patient characteristics, treatment details, and neuropathy outcomes were collected. Univariate and multivariate logistic regression analyses were performed to evaluate factors associated with grade\u2009\u2265\u20092 neuropathy. Statistical significance was defined as\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty-seven patients were included in the analysis, and 19 patients (33.3%) developed grade\u2009\u2265\u20092 neuropathy. In multivariate logistic regression, a history of diabetes mellitus was significantly associated with the development of grade\u2009\u2265\u20092 neuropathy (odds ratio 3.89, 95% confidence interval 1.06\u201314.3,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.041). No other clinical or treatment-related variables demonstrated significant associations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A history of diabetes mellitus may be associated with the development of grade\u2009\u2265\u20092 CIPN in patients with unresectable pancreatic cancer undergoing GnP therapy. Healthcare professionals should detect CIPN symptoms early and manage them appropriately, particularly in patients with diabetes mellitus.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-026-00572-4","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:18:05Z","timestamp":1775560685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors associated with peripheral neuropathy development during gemcitabine plus albumin-bound paclitaxel therapy as first-line treatment for unresectable pancreatic cancer: a retrospective evaluation"],"prefix":"10.1186","volume":"12","author":[{"given":"Tomoya","family":"Ban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"572_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"572_CR2","unstructured":"Cancer Information Service, National Cancer Center, Japan [Internet]. Tokyo: National Cancer Center; [cited 2024 Nov 13]. Available from: https:\/\/ganjoho.jp"},{"key":"572_CR3","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395:2008\u201320.","journal-title":"Lancet"},{"key":"572_CR4","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 2.2025 [Internet]. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2025 Feb 3 [cited 2025 Dec 9]. Available from: https:\/\/www.nccn.org"},{"key":"572_CR5","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403\u201313.","journal-title":"J Clin Oncol"},{"key":"572_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"572_CR7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S2666-7568(21)00255-5","volume":"2","author":"Y Kogure","year":"2021","unstructured":"Kogure Y, Iwasawa S, Saka H, Hamamoto Y, Kada A, Hashimoto H, et al. Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial. Lancet Healthy Longev. 2021;2:791\u2013800.","journal-title":"Lancet Healthy Longev"},{"key":"572_CR8","doi-asserted-by":"publisher","first-page":"728","DOI":"10.5009\/gnl18220","volume":"12","author":"MS You","year":"2018","unstructured":"You MS, Ryu JK, Choi YH, Choi JH, Huh G, Paik WH, et al. Efficacy of nab-paclitaxel plus gemcitabine and prognostic value of peripheral neuropathy in patients with metastatic pancreatic cancer. Gut Liver. 2018;12:728\u201335.","journal-title":"Gut Liver"},{"key":"572_CR9","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1159\/000524868","volume":"100","author":"M Catalano","year":"2022","unstructured":"Catalano M, Ramello M, Conca R, Aprile G, Petrioli R, Roviello G. Risk factors for nab-paclitaxel and gemcitabine-induced peripheral neuropathy in patients with pancreatic cancer. Oncology. 2022;100:384\u201391.","journal-title":"Oncology"},{"key":"572_CR10","first-page":"263","volume":"33","author":"Y Saito","year":"2025","unstructured":"Saito Y, Takekuma Y, Komatsu Y, Sugawara M. Identification of risk factors related to problematic peripheral neuropathy development in gemcitabine and nab-paclitaxel treatment for pancreatic cancer. Support Care Cancer. 2025;33:263.","journal-title":"Support Care Cancer"},{"key":"572_CR11","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [Internet]. Bethesda (MD): National Cancer Institute; 2017 Nov [cited 2025 Dec 9]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"key":"572_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1124\/dmd.120.000126","volume":"49","author":"Y Katsube","year":"2021","unstructured":"Katsube Y, Tsujimoto M, Koide H, Hira D, Ikeda Y, Minegaki T, et al. In vitro evidence of potential interactions between CYP2C8 and candesartan acyl-\u03b2-D-glucuronide in the liver. Drug Metab Dispos. 2021;49:289\u201397.","journal-title":"Drug Metab Dispos"},{"key":"572_CR13","doi-asserted-by":"publisher","first-page":"328","DOI":"10.5414\/CP203180","volume":"56","author":"Y Katsube","year":"2018","unstructured":"Katsube Y, Hira D, Tsujimoto M, Koide H, Minegaki T, Ikeda Y, et al. Concomitant administration of candesartan cilexetil in patients on paclitaxel and carboplatin combination therapy increases risk of severe neutropenia. Int J Clin Pharmacol Ther. 2018;56:328\u201336.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"572_CR14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2165\/00003088-200746080-00005","volume":"46","author":"Y Ohno","year":"2007","unstructured":"Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet. 2007;46:681\u201396.","journal-title":"Clin Pharmacokinet"},{"key":"572_CR15","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","volume":"31","author":"B Jordan","year":"2020","unstructured":"Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P, et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol. 2020;31:1306\u201319.","journal-title":"Ann Oncol"},{"key":"572_CR16","first-page":"38","volume":"15","author":"MR Jones","year":"2020","unstructured":"Jones MR, Urits I, Wolf J, Corrigan D, Colburn L, Peterson E, et al. Drug-induced peripheral neuropathy: a narrative review. Curr Clin Pharmacol. 2020;15:38\u201348.","journal-title":"Curr Clin Pharmacol"},{"key":"572_CR17","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1200\/JCO.2015.66.2346","volume":"34","author":"DL Hershman","year":"2016","unstructured":"Hershman DL, Till C, Wright JD, Awad D, Ramsey SD, Barlow WE, et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group clinical trials. J Clin Oncol. 2016;34:3014\u201322.","journal-title":"J Clin Oncol"},{"key":"572_CR18","doi-asserted-by":"publisher","first-page":"e2036695","DOI":"10.1001\/jamanetworkopen.2020.36695","volume":"4","author":"D Mizrahi","year":"2021","unstructured":"Mizrahi D, Park SB, Li T, Timmins HC, Trinh T, Au K, et al. Hemoglobin, body mass index, and age as risk factors for paclitaxel- and oxaliplatin-induced peripheral neuropathy. JAMA Netw Open. 2021;4:e2036695.","journal-title":"JAMA Netw Open"},{"key":"572_CR19","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/aje\/kwk052","volume":"165","author":"E Vittinghoff","year":"2007","unstructured":"Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165:710\u20138.","journal-title":"Am J Epidemiol"},{"key":"572_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transpl"},{"key":"572_CR21","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00280-016-2972-3","volume":"77","author":"H Ueno","year":"2016","unstructured":"Ueno H, Ikeda M, Ueno M, Mizuno N, Ioka T, Omuro Y, et al. Phase I\/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2016;77:595\u2013603.","journal-title":"Cancer Chemother Pharmacol"},{"key":"572_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejca.2015.10.017","volume":"52","author":"D Goldstein","year":"2016","unstructured":"Goldstein D, Von Hoff DD, Moore M, Greeno E, Tortora G, Ramanathan RK, et al. Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: a subset analysis from a randomised phase III trial (MPACT). Eur J Cancer. 2016;52:85\u201391.","journal-title":"Eur J Cancer"},{"key":"572_CR23","first-page":"419","volume":"63","author":"SB Park","year":"2013","unstructured":"Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63:419\u201337.","journal-title":"CA Cancer J Clin"},{"key":"572_CR24","volume-title":"Harrison\u2019s Principles of Internal Medicine","year":"2022","unstructured":"Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. Harrison\u2019s Principles of Internal Medicine. 21st ed. New York: McGraw-Hill Education; 2022.","edition":"21"},{"issue":"6","key":"572_CR25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/ncpneuro0504","volume":"3","author":"G Said","year":"2007","unstructured":"Said G. Diabetic neuropathy\u2014a review. Nat Clin Pract Neurol. 2007;3(6):331\u201340.","journal-title":"Nat Clin Pract Neurol"},{"key":"572_CR26","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/cncr.32175","volume":"125","author":"KA Nyrop","year":"2019","unstructured":"Nyrop KA, Deal AM, Reeder-Hayes KE, Shachar SS, Reeve BB, Choi SK, et al. Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: current clinical practice. Cancer. 2019;125:2945\u201354.","journal-title":"Cancer"},{"key":"572_CR27","first-page":"4771","volume":"27","author":"AC Tan","year":"2019","unstructured":"Tan AC, McCrary JM, Park SB, Trinh T, Goldstein D. Chemotherapy-induced peripheral neuropathy: patient-reported outcomes compared with NCI-CTCAE grade. Support Care Cancer. 2019;27:4771\u20137.","journal-title":"Support Care Cancer"},{"key":"572_CR28","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1186\/s12885-018-4869-5","volume":"18","author":"Z Ghoreishi","year":"2018","unstructured":"Ghoreishi Z, Keshavarz S, Jafarabadi MA, Fathifar Z, Goodman KA, Esfahani A. Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer. BMC Cancer. 2018;18:958.","journal-title":"BMC Cancer"},{"key":"572_CR29","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1093\/jnci\/djp413","volume":"101","author":"M Bryd\u00f8y","year":"2009","unstructured":"Bryd\u00f8y M, Oldenburg J, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst. 2009;101:1682\u201395.","journal-title":"J Natl Cancer Inst"},{"key":"572_CR30","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/cpt.674","volume":"102","author":"K Agergaard","year":"2017","unstructured":"Agergaard K, Mau-S\u00f8rensen M, Stage TB, J\u00f8rgensen TL, Hassel RE, Steffensen KD, et al. Clopidogrel\u2013paclitaxel drug\u2013drug interaction: a pharmacoepidemiologic study. Clin Pharmacol Ther. 2017;102:547\u201353.","journal-title":"Clin Pharmacol Ther"},{"key":"572_CR31","doi-asserted-by":"publisher","first-page":"1327318","DOI":"10.3389\/fonc.2024.1327318","volume":"14","author":"S Lixian","year":"2024","unstructured":"Lixian S, Xiaoqian Y, Luyan G, Lizhi Z, Rui D, Hongyue Y, Caijie Z, Fenghui Y. Risk factors of paclitaxel-induced peripheral neuropathy in patients with breast cancer: a prospective cohort study. Front Oncol. 2024;14:1327318.","journal-title":"Front Oncol"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-026-00572-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00572-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00572-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:35:39Z","timestamp":1781645739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-026-00572-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["572"],"URL":"https:\/\/doi.org\/10.1186\/s40780-026-00572-4","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical guidelines for medical research involving human subjects and approved by the relevant institutional review boards. Approval was obtained from the Clinical Trial Review Committee of Rakuwakai Otowa Hospital (control number: Rakugaku-Rin-01-000358). Individual consent was not obtained directly from the patients in this study; however, information regarding enrollment was appropriately disclosed and participants were provided with an opportunity to refuse enrollment. Clinical trial number: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors provide their consent for publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}